This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients (NCT00900146), a randomized phase 2, phase 3 study. The primary outcome is Number of Participants With Adverse Events (AEs), Serious Adverse Events, Death and Clinical Significant AEs During 4 Months (Period II).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT00900146 |
| Phase | Phase 2, Phase 3 |
| Condition | Diabetes Mellitus, Type 2 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Enrollment | 556 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Novartis |
| Results posted | Yes |
2. Clinical Question
Population
Adults with type 2 diabetes treated with metformin were the intended study population. The registry describes patients already receiving maximum-dose metformin in its summary, and the treatment groups continued a stable metformin dose. It does not report the full eligibility criteria in the information available in the registry record, so details such as disease duration, baseline glucose levels, or exclusions cannot be characterized.
Intervention
The intervention was monthly subcutaneous canakinumab added to metformin. The dose-finding period included canakinumab doses of 5 mg, 15 mg, 50 mg, and 150 mg. The study description also refers to an extension at a selected dose, but extension results are not reported in the registry record.
Comparator
The comparator group received matching placebo injections alongside stable metformin. This design allows the posted safety counts to be read by randomized treatment group, although the registry record does not provide an adjusted comparison or a statistical test of differences.
Primary question
The primary outcome asks how many participants experienced adverse events, serious adverse events, death, or clinically significant adverse events during 4 months (Period II). The record gives serious and other adverse-event counts by arm, but it does not report all categories named in the primary outcome as separate results. The central question is therefore a safety-description question in the posted results, rather than a quantified estimate of comparative treatment effect.
3. Trial Design
The registry describes a randomized, double-blind, placebo-controlled, multicenter, parallel-group study, with phase listed as Phase 2 and Phase 3. Enrollment is recorded as 556. The sponsor is Novartis. The study began in 2009-04, and primary completion is recorded as 2010-11. Its current status in the registry record is terminated; a reason for termination is not reported in the registry record.
The study was designed around a four-month dose-finding period, followed in the brief description by a 24 to 48 month extension at a selected dose. In the dose-finding period, participants in the canakinumab groups received monthly injections at 5 mg, 15 mg, 50 mg, or 150 mg, while the placebo group received matching injections. All groups continued stable metformin. The extension is described as part of the study, but its selected dose, conduct, and results are not reported in the registry record.
Random allocation and parallel groups support comparisons between assigned regimens, while placebo control provides a reference group receiving metformin without active canakinumab. The registry lists quadruple masking, but does not identify which roles were masked or describe the procedures used to maintain masking. The stated primary outcome concerns adverse events during 4 months (Period II). The record also lists secondary meal-test outcomes involving glucose, insulin, and C-peptide. It does not provide the full statistical analysis plan or report an analysis for these outcomes.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: A total of 556 patients were randomized in Period II. 5 patients one in each 5, 15, 50mg Canakinumab arms and 2 in Placebo were randomized in error, but never received study treatment. All tables reflect the 551 treated patients.
Dose Finding: Period II (4 Months)
| Stage | Canakinumab 5 mg + Metformin | Canakinumab 15 mg + Metformin | Canakinumab 50 mg + Metformin | Canakinumab 150 mg + Metformin | Placebo + Metformin |
|---|---|---|---|---|---|
| STARTED | 93 | 95 | 92 | 92 | 179 |
| Full Analysis Set (FAS)/Safety | 93 | 95 | 92 | 92 | 179 |
| COMPLETED | 88 | 93 | 87 | 90 | 167 |
| NOT COMPLETED | 5 | 2 | 5 | 2 | 12 |
Reasons for not completing this period:
| Reason | Canakinumab 5 mg + Metformin | Canakinumab 15 mg + Metformin | Canakinumab 50 mg + Metformin | Canakinumab 150 mg + Metformin | Placebo + Metformin |
|---|---|---|---|---|---|
| Withdrawal by Subject | 2 | 2 | 5 | 1 | 9 |
| Lost to Follow-up | 2 | 0 | 0 | 1 | 3 |
| Administrative problems | 1 | 0 | 0 | 0 | 0 |
Intermediate: Period III
| Stage | Canakinumab 5 mg + Metformin | Canakinumab 15 mg + Metformin | Canakinumab 50 mg + Metformin | Canakinumab 150 mg + Metformin | Placebo + Metformin |
|---|---|---|---|---|---|
| STARTED | 87 | 93 | 84 | 90 | 167 |
| Safety Set | 86 | 92 | 84 | 90 | 166 |
| COMPLETED | 0 | 0 | 0 | 0 | 0 |
| NOT COMPLETED | 87 | 93 | 84 | 90 | 167 |
Reasons for not completing this period:
| Reason | Canakinumab 5 mg + Metformin | Canakinumab 15 mg + Metformin | Canakinumab 50 mg + Metformin | Canakinumab 150 mg + Metformin | Placebo + Metformin |
|---|---|---|---|---|---|
| Withdrawal by Subject | 0 | 1 | 0 | 0 | 3 |
| Lost to Follow-up | 2 | 0 | 0 | 0 | 1 |
| Administrative problems | 85 | 92 | 84 | 90 | 163 |
Analysis population for the primary outcome, as defined in the registry: The safety set (SAF) included all patients who received at least one dose of study medication during Period II.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Canakinumab 5 mg + Metformin | Canakinumab 15 mg + Metformin | Canakinumab 50 mg + Metformin | Canakinumab 150 mg + Metformin | Placebo + Metformin | Total |
|---|---|---|---|---|---|---|---|
| Participants analysed | 93 | 95 | 92 | 92 | 179 | 551 | |
| Age Continuous | years | 53.5 (SD 10.27) | 55.5 (SD 9.70) | 53.0 (SD 9.29) | 53.7 (SD 10.36) | 54.3 (SD 10.15) | 54.1 (SD 9.99) |
| Sex: Female, Male: Female | Participants | 38 | 46 | 47 | 35 | 74 | 240 |
| Sex: Female, Male: Male | Participants | 55 | 49 | 45 | 57 | 105 | 311 |
6. Primary Endpoint
The registry lists the primary outcome as Number of Participants With Adverse Events (AEs), Serious Adverse Events, Death and Clinical Significant AEs During 4 Months (Period II), measured over 4 months (Period II).
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | Participants |
| Endpoint classification | Binary Endpoint |
The primary outcome is the number of participants with adverse events, serious adverse events, death, and clinically significant adverse events during 4 months (Period II). The registry defines an adverse event broadly as an unfavorable, unintended diagnosis, symptom, sign, syndrome, or disease that newly occurs during the study or worsens from baseline. Serious events are defined by consequences such as death, life-threatening illness, hospitalization, persistent or significant disability, congenital anomalies, or other conditions judged by investigators to represent significant hazards.
Counting participants with events is a direct way to describe how many people in each treatment group experienced an event during the stated observation period. It is useful for a safety outcome because it keeps the result at the participant level rather than treating multiple events in one person as separate people. However, a count alone does not describe event timing, duration, recurrence, severity beyond the stated categories, or exposure-adjusted rates. Nor does it establish that treatment caused an event.
The registry identifies the safety set as participants who received at least one dose of study medication during Period II. The posted results give serious and other adverse-event counts by arm. Separate results for deaths and clinically significant adverse events are not reported in the registry record, so those parts of the primary outcome cannot be evaluated from the posted counts.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The posted safety results are descriptive. For serious adverse events, the registry records 3 of 93 participants in the canakinumab 5 mg plus metformin group, 1 of 95 in the 15 mg group, 5 of 92 in the 50 mg group, 7 of 92 in the 150 mg group, and 8 of 179 in the placebo plus metformin group. For other adverse events, it records 9 of 93, 9 of 95, 15 of 92, 8 of 92, and 26 of 179, respectively. These are counts of participants with events as classified in the registry record.
Those numbers can be read within their treatment groups, but they do not by themselves establish whether the underlying event risks differ. The registry does not report confidence intervals, p-values, adjusted comparisons, or an analysis method for these results. Without such information, the precision of a between-group contrast and the statistical compatibility of the observed counts with no difference cannot be assessed from the registry record. The counts should not be converted into claims of treatment benefit or harm.
The primary outcome title includes death and clinically significant adverse events, but separate results for those categories are not reported in the registry record. A null death entry is not a count of zero; it means a death result is not available in this record. The serious-event terms listed include several events at 1.1% each, but those entries do not supply a complete event-by-arm breakdown or clarify all denominators. They should be read as selected terms, not as a comprehensive account of safety.
The group counts also reflect the safety-set definition, which includes participants receiving at least one dose during Period II. They do not establish that every randomized participant contributed to the safety summaries. The registry does not describe missing outcome handling, follow-up completeness, or reasons participants may have been absent from an analysis. Therefore, the numbers describe the posted safety set and period, not necessarily the full randomized population or the longer extension.
Several doses were studied, creating multiple possible comparisons with placebo. No reported inferential analysis identifies a prespecified primary contrast among those doses. The descriptive pattern across groups should not be treated as evidence of a dose-response relationship. Such a claim would require a defined analysis and attention to uncertainty and multiplicity, neither of which is reported in the registry record.
9. Statistical Methods Explained
What does a participant count represent?
As a general statistical principle, a participant count for an adverse-event category records whether each person met that category during the specified observation period. A person with more than one event may still contribute as one participant to a count of participants with any event. The registry outcome is framed in participant counts, and its safety set includes people who received at least one dose during Period II. The posted group counts should therefore be interpreted as counts within that set, not as a tally of every event occurrence.
For this trial, the registry reports serious adverse events separately from other adverse events. These categories should not be conflated. The broad definition of an adverse event includes a wide range of unfavorable medical occurrences, while the serious category depends on specified consequences or investigator judgment. The record does not give enough detail to reconstruct every classification decision or determine whether categories overlap in the underlying participant records.
Why does uncertainty matter for group comparisons?
As a general statistical principle, a confidence interval describes the range of effect sizes reasonably compatible with the observed data under a specified method and assumptions. It conveys precision, not the probability that a treatment works. A count without an interval gives limited information about how precisely a group difference is estimated. The registry record does not report confidence intervals for the posted safety counts.
As a general principle, a statistical test evaluates data against a stated hypothesis and analysis plan. A p-value, when reported, does not quantify the size or clinical importance of an effect. No p-values or comparative tests for the primary safety counts are reported in the registry record. The groups can be described individually, but a formal conclusion about differences cannot be drawn from the counts alone.
How should multiple doses be handled?
As a general statistical principle, comparing several dose groups with a shared control creates multiple opportunities to find an apparently unusual result by chance. Multiplicity procedures or a clearly stated hierarchy of hypotheses can help govern interpretation. The registry lists four canakinumab dose groups and placebo, but the statistical plan for comparisons and any multiplicity adjustment are not reported in the registry record. It is also not reported which dose, if any, was designated for a single confirmatory comparison.
The pattern of counts across the dose groups is not, on its own, a formal dose-response analysis. A dose-response assessment would need a defined model or planned contrast, along with uncertainty estimates and assumptions. No such analysis is reported for the primary outcome. General statistical reasoning therefore supports treating the posted arm-specific counts as descriptive rather than as a test of a trend.
What do the planning illustrations mean?
As a general statistical principle, sample-size calculations are planning tools. The registry’s described planning assumptions use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. Such calculations do not describe the trial’s observed statistical power. They are not a substitute for the original design rationale, and they do not show that the study was planned around the primary safety outcome.
The registry record does not report the trial’s sample-size justification or the effect size assumed in its original design. The planning assumptions described for the accompanying illustrations should therefore be understood as planning illustrations, not as evidence of the protocol’s prespecified target or of the ability to detect a particular safety difference.
What analysis details are unavailable?
The registry lists 21 outcome measures, including primary and secondary outcomes, but reports no analysis records. The full statistical analysis plan, covariate adjustments, handling of repeated measurements, missing-data methods, and interim-analysis plans are not reported in the registry record. The record also does not state whether any outcome definitions changed during the study. These omissions constrain interpretation: readers cannot verify which analyses were prespecified, how the listed outcomes were prioritized, or whether the posted counts are complete for every planned category.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists multiple canakinumab dose groups and placebo, as well as secondary outcomes from meal tests. In general, testing many group contrasts or outcomes increases the chance of finding an apparently notable result by chance unless the analysis plan accounts for multiplicity. The registry record does not report a hierarchy of hypotheses, a multiplicity adjustment, or which comparisons were designated as primary for analysis. The posted results therefore do not support interpreting a pattern across doses as a confirmatory dose-response finding.
Missing-data handling is not reported in the registry record. It does not describe how participants without a recorded outcome were handled, whether follow-up was complete, or whether missingness differed among groups. The safety-set definition includes participants who received at least one dose during Period II, but the record does not provide a complete account of how the randomized population maps to each outcome analysis.
The primary outcome names several event categories, while the posted counts distinguish serious from other adverse events. Separate results for deaths and clinically significant adverse events are not reported in the registry record. The record also does not report analysis populations for the secondary outcomes or methods for handling repeated meal-test measurements. These gaps mean that the posted safety data can be described, but the completeness and prespecification of the full outcome analysis cannot be established.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Canakinumab 5 mg + Metformin | 3 | 93 | 3.2% |
| Canakinumab 15 mg + Metformin | 1 | 95 | 1.1% |
| Canakinumab 50 mg + Metformin | 5 | 92 | 5.4% |
| Canakinumab 150 mg + Metformin | 7 | 92 | 7.6% |
| Placebo + Metformin | 8 | 179 | 4.5% |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Canakinumab 5 mg + Metformin | 9 of 93 |
| Canakinumab 15 mg + Metformin | 9 of 95 |
| Canakinumab 50 mg + Metformin | 15 of 92 |
| Canakinumab 150 mg + Metformin | 8 of 92 |
| Placebo + Metformin | 26 of 179 |
Most frequent serious adverse event terms
| Event term | Organ system | Canakinumab 5 mg + Metformin | Canakinumab 15 mg + Metformin | Canakinumab 50 mg + Metformin | Canakinumab 150 mg + Metformin | Placebo + Metformin |
|---|---|---|---|---|---|---|
| Cholecystitis | Hepatobiliary disorders | 0 of 93 | 0 of 95 | 1 of 92 | 0 of 92 | 1 of 179 |
| Calculus ureteric | Renal and urinary disorders | 0 of 93 | 0 of 95 | 1 of 92 | 1 of 92 | 0 of 179 |
| Acute left ventricular failure | Cardiac disorders | 0 of 93 | 0 of 95 | 0 of 92 | 0 of 92 | 1 of 179 |
| Angina pectoris | Cardiac disorders | 0 of 93 | 0 of 95 | 0 of 92 | 1 of 92 | 0 of 179 |
| Angina unstable | Cardiac disorders | 0 of 93 | 0 of 95 | 0 of 92 | 0 of 92 | 1 of 179 |
| Atrial fibrillation | Cardiac disorders | 0 of 93 | 0 of 95 | 0 of 92 | 1 of 92 | 0 of 179 |
| Cardiac failure congestive | Cardiac disorders | 0 of 93 | 0 of 95 | 0 of 92 | 0 of 92 | 1 of 179 |
| Coronary artery disease | Cardiac disorders | 0 of 93 | 0 of 95 | 0 of 92 | 0 of 92 | 1 of 179 |
| Myocardial infarction | Cardiac disorders | 0 of 93 | 0 of 95 | 0 of 92 | 0 of 92 | 1 of 179 |
| Colonic polyp | Gastrointestinal disorders | 0 of 93 | 0 of 95 | 1 of 92 | 0 of 92 | 0 of 179 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Canakinumab 5 mg + Metformin | Canakinumab 15 mg + Metformin | Canakinumab 50 mg + Metformin | Canakinumab 150 mg + Metformin | Placebo + Metformin |
|---|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | 5 of 93 | 4 of 95 | 9 of 92 | 4 of 92 | 15 of 179 |
| Urinary tract infection | Infections and infestations | 3 of 93 | 4 of 95 | 5 of 92 | 5 of 92 | 11 of 179 |
| Diarrhoea | Gastrointestinal disorders | 2 of 93 | 2 of 95 | 5 of 92 | 0 of 92 | 3 of 179 |
Serious events with the highest arm-level rate: angina pectoris (1.1%), atrial fibrillation (1.1%), colonic polyp (1.1%), cholecystitis (1.1%), breast abscess (1.1%).
The serious adverse-event figures are participant counts within each treatment group: 3 of 93 for canakinumab 5 mg plus metformin, 1 of 95 for 15 mg plus metformin, 5 of 92 for 50 mg plus metformin, 7 of 92 for 150 mg plus metformin, and 8 of 179 for placebo plus metformin. The corresponding counts for other adverse events are 9 of 93, 9 of 95, 15 of 92, 8 of 92, and 26 of 179. These figures describe the safety set during the stated period; they are not adjusted comparisons.
Seriousness is a classification based on event consequences or investigator judgment, not a measure of how often all adverse events occurred. The registry’s primary outcome also mentions death and clinically significant events, but separate counts for those categories are not reported in the registry record. Death entries are unavailable rather than evidence of zero deaths. The listed serious-event terms, each reported at 1.1%, are selected terms and do not provide a full breakdown by treatment group.
As a general statistical principle, differences between raw counts can reflect both underlying event frequency and the number of people observed in each group. Without reported uncertainty intervals, comparative tests, and complete outcome follow-up information, the counts alone cannot establish a reliable treatment difference.
12. What the Result Does, and Does Not, Mean
The registry record establishes the study’s setting and the categories of information posted: a randomized, placebo-controlled comparison of monthly canakinumab doses alongside metformin, with a primary safety outcome during 4 months (Period II). It reports serious and other adverse-event counts for the safety set. Those counts can be used to describe what was recorded in each group during that period.
The counts do not establish that canakinumab caused or prevented an event, nor do they show that the treatment groups had equivalent safety. A lack of a reported statistical test is not evidence of no difference. Conversely, a numerical difference in counts is not, by itself, evidence of a real or clinically important effect. The registry does not give the confidence intervals, p-values, or adjusted comparisons needed to characterize statistical uncertainty in group contrasts.
The primary outcome includes categories for which separate results are unavailable: deaths and clinically significant adverse events are not reported in the registry record. No efficacy result is provided in the primary outcome information summarized by the registry record. Although secondary outcomes address glucose, insulin, and C-peptide measurements following meal tests, their results and analysis details are not included in the record.
The trial description refers to a longer extension at a selected dose, but extension findings are not reported in the registry record. The posted four-month safety counts cannot be used to infer long-term safety, outcomes after the dose-finding period, or the effects of a selected extension dose. Overall, the record supports a limited descriptive account of safety counts, not a broad conclusion about comparative safety or efficacy.
13. Why This Trial Matters Statistically
This trial is statistically notable for its multi-arm dose-finding structure and its placebo comparison on a background of metformin. Multiple doses can provide information about how outcomes vary across regimens, but they also raise questions about which contrasts were planned and how multiplicity was handled. The registry record does not report those analysis details, making it important to distinguish a descriptive pattern from a prespecified inferential result.
The primary outcome is safety-focused and defined as participant counts across several categories. This illustrates why outcome labels and posted results must be read together: the primary outcome names adverse events, serious adverse events, deaths, and clinically significant adverse events, while the available group results separate serious from other adverse events. Not all named components have separate posted counts.
The record also highlights the difference between a study’s intended scope and the results available for interpretation. Its description includes a dose-finding period and a longer extension, but the record does not report extension results, a statistical analysis plan, or analyses for the listed outcomes. Those absences limit what can be concluded even though group-specific counts are available. For clinical researchers and biostatisticians, the main lesson is to keep the estimand, analysis population, outcome definition, and reported uncertainty aligned when interpreting multi-arm safety data.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The registry record provides limited information about how the study was conducted and analyzed. It identifies randomization, quadruple masking, and a parallel design, but does not describe the randomization procedure, concealment, or which participants and study personnel were masked. Full eligibility criteria and baseline characteristics are not reported in the registry record.
The record does not explain why the study was terminated. Although it describes an extension at a selected dose, the selected dose, extension population, follow-up, and outcomes are not reported in the registry record. The posted primary outcome is limited to 4 months (Period II), so it cannot characterize longer-term outcomes.
Important analysis details are also unavailable. The statistical analysis plan, sample-size justification, missing-data methods, interim analyses, and multiplicity procedures are not reported in the registry record. No comparative estimates, confidence intervals, or p-values are reported for the safety counts. The primary outcome names deaths and clinically significant adverse events, but separate results for those categories are not reported. These limitations prevent a complete assessment of outcome completeness, precision, and comparative effects.
The registry reports counts for participants with serious and other adverse events, but does not provide event timing, recurrent-event counts, exposure-adjusted rates, or full treatment-specific details for the listed serious-event terms. The counts should therefore be interpreted narrowly as posted participant counts in the defined safety set, rather than as a comprehensive safety analysis.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients — NCT00900146.
- Registry record last updated 2012-02-20; status last verified 2012-01.
- Results first posted 2012-02-20.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
This randomized, double-blind, placebo-controlled, multicenter, parallel-group study evaluated monthly subcutaneous canakinumab at 5 mg, 15 mg, 50 mg, and 150 mg alongside metformin, with placebo plus metformin as the comparator. The registry lists Phase 2 and Phase 3 and records enrollment of 556. The study began in 2009-04, primary completion is recorded as 2010-11, and its status is terminated.
The primary outcome concerns adverse events, serious adverse events, death, and clinically significant adverse events during 4 months (Period II). The posted results give group counts for serious and other adverse events in the safety set. Separate death and clinically significant adverse-event results, comparative statistical analyses, and extension results are not reported in the registry record. The record also does not report the statistical analysis plan, missing-data methods, or multiplicity procedures.